Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

摘要: Zoledronic acid (Zometa, ZOL) is increasingly used to treat tumour-induced bone disease, and also reported have antiangiogenic properties in vivo. In this study, we investigated the correlations between changes proangiogenic cytokine, vascular endothelial growth factor (VEGF), markers of resorption a cohort patients with metastatic following single infusion ZOL. Twenty-four consecutive selected cancer scintigraphic radiographic evidence metastases were treated for first time 4 mg Patients considered ineligible if they had received any steroid therapy, radiotherapy, chemotherapy, immunotherapy or haemopoietic factors weeks before during study period. Circulating levels VEGF beta crosslinked type I collagen C-telopeptide (betaCTX) measured at base-line 1, 2, 7 21 days ZOL infusion. The majority our (23/24) developed significant reduction circulating betaCTX just 1 day after zoledronic infusion, median percentage decrease 67.05% (95% CI, 52.39%; 76.27%). This persisted all points almost subjects patient population (day 95.8%; 7, 100%; 21, 91.7%). 2 was 85.67% 78.23%; 90.16%); 67.38% 67.38%; 86.98); 76.89% 35.00%; 83.16%). Moreover, linear regression model variance analysis demonstrated statistically correlation each (1, infusion). present work demonstrates that able induce rapid long lasting plasma included patients. Furthermore, found there treatment. Future clinical trials should be designed prospectively evaluate prognostic role response predict skeletal outcome.